Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16293473 | 0.82 | TERT (0.39) | KDM4EFERMT2 | |
| SCHEMBL16305531 | 0.82 | TERT (0.39) | KDM4EFERMT2 | |
| SCHEMBL17984983 | 0.80 | CHRM2 (0.38) | KDM4EFERMT2 | |
| SCHEMBL17984971 | 0.77 | CHRM2 (0.40) | KDM4EFERMT2 | |
| SCHEMBL16305536 | 0.77 | CHRM2 (0.40) | KDM4EFERMT2 | |
| SCHEMBL17984970 | 0.74 | CHRM2 (0.32) | — | |
| SCHEMBL18831149 | 0.71 | SRC (0.44) | MEN1KMT2A | |
| SCHEMBL18831150 | 0.71 | SRC (0.44) | MEN1KMT2A | |
| SCHEMBL10616591 | 0.70 | KDM4E (0.47) | MAP1LC3BKDM4EMEN1KMT2APSMD14 | |
| SCHEMBL10616595 | 0.70 | KDM4E (0.47) | MAP1LC3BKDM4EMEN1KMT2APSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237037-A1 | INHIBITORS OF HISTONE DEMETHYLASES | KDM1B, KDM1A, KDM3A | MAP1LC3B 2663/4885KDM4E 14/4885CYP2D6 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.